Format
Sort by

Send to

Choose Destination

Search results

Items: 2

1.

MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers.

Fricke SL, Payne SN, Favreau PF, Kratz JD, Pasch CA, Foley TM, Yueh AE, Van De Hey DR, Depke MG, Korkos DP, Sha GC, DeStefanis RA, Clipson L, Burkard ME, Lemmon KK, Parsons BM, Kenny PA, Matkowskyj KA, Newton MA, Skala MC, Deming DA.

Mol Cancer Ther. 2019 Feb;18(2):346-355. doi: 10.1158/1535-7163.MCT-18-0510. Epub 2018 Nov 13.

PMID:
30425131
2.

The aryl hydrocarbon receptor as an antitumor target of synthetic curcuminoids in colorectal cancer.

Megna BW, Carney PR, Depke MG, Nukaya M, McNally J, Larsen L, Rosengren RJ, Kennedy GD.

J Surg Res. 2017 Jun 1;213:16-24. doi: 10.1016/j.jss.2017.02.010. Epub 2017 Feb 22.

Supplemental Content

Loading ...
Support Center